・業績
 ・受賞・表彰
 ・資格・認定
 ・認定施設
 業績 [ 2021年 ] 過去の業績はこちらから

原著論文(英文)
1. Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K, Imamura CK, Okita K, Kagami Y, Tanaka R, Nakagawa K, Fujii H, Boku N, Wada M, Akechi T, Iihara H, Ohtani S, Okuyama A, Ozawa K, Kim YI, Sasaki H, Shima Y, Takeda M, Nagasaki E, Nishidate T, Higashi T, Hirata K. Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol. 2021; 26(1): 1-17.
2. Yamada Y. Matsuhashi, Fujii H, Makiyama A, Iihara H, Takahashi T, Watanabe D, Kiyama S, Kobayashi R, Suzuki A, Yoshida K. Impact of Anti-angiogenic Agents on Chemotherapy Efficacy in Patients With Metastatic Colorectal Cancer: Second-line FOLFIRI plus Bevacizumab or Aflibercept. Anticancer Res. 2021; 41(1): 533-541.
3. Kitagawa J, Kobayashi R, Nagata Y, Kasahara S, Ono T, Sawada M, Ohata K, Kato-Hayashi H, Hayashi H, Shimizu M, Itoh Y, Tsurumi H, Suzuki A. Polaprezinc for prevention of oral mucositis in patients receiving chemotherapy followed by hematopoietic stem cell transplantation: a multi-institutional randomized controlled trial. Int J Cancer. 2021; 148(6): 1462-1469.
4. Suzuki K, Okada H, Tomita H, Sumi K, Kakino Y, Yasuda R, Kitagawa Y, Fukuta T, Miyake T, Yoshida S, Suzuki A, Ogura S. Possible Involvement of Syndecan-1 in the State of COVID-19 Related to Endothelial Injury. Thromb J. 2021; 19(1): 5.
5. Hayashi T, Shimokawa M, Matsuo K, Iihara H, Kawada K, Nakano T, Egawa T. Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis. BMC Cancer. 2021; 21(1): 74.
6. Sato Y, Iihara H, Kinomura M, Hirose C, Fujii H, Endo J, Yanase K, Kaito D, Sasaki Y, Gomyo T, Sakai C, Iwai M, Tsuboi Y, Ishihara T, Kobayashi R, Ohno Y, Suzuki A. Primary prophylaxis of febrile neutropenia with pegfilgrastim in small-cell lung cancer patients receiving amrubicin as second-line therapy. Anticancer Res. 2021; 42(3): 1615-1620.
7. Hayashi T, Shimokawa M, Matsuo K, Nishimura J, Iihara H, Nakano T, Egawa T. 5HT3RA plus dexamethasone plus aprepitant for controlling delayed chemotherapy-induced nausea and vomiting in colorectal cancer. Cancer Sci. 2021; 112(2): 744-750.
(in press)
1. Harada S, Niwa T, Hoshino Y, Fujibayashi A, Suzuki A. Influence of switching from intravenous to oral administration on serum voriconazole concentration. J Clin Pharm Ther. (in press)
2. Iihara H, Hirose C, Funaguchi N, Endo J, Ito F, Yanase K, Kaito D, Sasaki Y, Gomyo T, Sakai C, Ohno Y, Suzuki A. Evaluation of Clinical Pharmacist Interventions for Adverse Events in Hospitalized Patients with Thoracic Cancer Receiving Cancer Chemotherapy. Mol Clin Oncol. (in press)
3. Shimizu S, Hayashi Y, Nishida S, Fujii H, Nakamura M, Yoshikura N, Nagano A, Kitagawa J, Kanemura N, Mizutani K, Kobayashi R, Ishihara T, Hayashi H, Shimohata T, Sugiyama T, Suzuki A. Albumin-bilirubin score for predicting neuropsychiatric symptoms in patients receiving ifosfamide-based chemotherapy. J Clin Pharm Ther. (in press)
4. Suzuki K, Fujii H, Yamauchi T, Kato-Hayashi H, Ishihara M, Iihara H, Hirose C, Nishida S, Funato M, Kobayashi R, Yasuda K, Ino Y, Tamaki H, Yamashita S, Iguchi K, Noguchi Y, Teramachi H, Takada J, Kubota M, Ibuka T, Araki H, Shimizu M, Suzuki A. Questionnaire survey for identification of meal habits influencing adherence to oral 5-aminosalicylic acid regimens in patients with ulcerative colitis. J Pharm Pract. (in press)
5. Sampei S, Okada H, Tomita H, Takada C, Suzuki K, TKinoshita T, Kobayashi R, Fukuda H, Kawasaki Y, Nishio A, Yano H, Muraki I, Fukuda Y, Suzuki K, Miyazaki N, Watanabe T, Doi T, Yoshida T, Suzuki A, Yoshida S, Kushimoto S, Ogura S. Endothelial Glycocalyx Disorders May Be Associated with Extended Inflammation During Endotoxemia in a Diabetic Mouse Model. Front Cell Dev Biol. (in press)
6. Sakai C, Shimokawa M, Iihara H, Fujita Y, Ikemura S, Hirose C, Kotake M, Funaguchi N, Gomyo T, Imai H, Hakamata J, Kaito D, Minato K, Arai T, Kawazoe H, Suzuki A, Ohno Y, Okura H. Low-Dose Olanzapine Plus Graniseteron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies. Oncologist. (in press)
7. Watanabe D, Fujii H, Yamada Y, Matsuhashi N, Makiyama A, Iihara H, Takahashi T, Kiyama S, Kobayashi R, Yoshida K, Suzuki A. Association of albumin-bilirubin score in patients with colorectal cancer receiving later-line chemotherapy with regorafenib. Int J Clin Oncol. (in press)

原著論文(和文)
1. 山田紘嗣、山田悠人、小林亮、林秀樹、鈴木昭夫、上野隆弘.光触媒を利用した抗がん薬分解フィルムの開発.癌と化学療法.(in press)

著書
1. 飯原大稔(分担執筆).吉村知哲、田村和夫(監修).がん薬物療法副作用管理マニュアル 第2版、「悪心・嘔吐・食欲不振」p46-58、2021.医学書院

総説等
1. 山田友奈美、藤井宏典、飯原大稔.特集・Evidence Update 2020最新の薬物治療のエビデンスを付加的に利用する「エキスパートが注目する最新エビデンスをアップデート!:大腸癌治療薬」.薬局72: p159-164、2021.南山堂

シンポジウム
1. 安田浩二.COVID-19下における職員の感染予防に配慮した薬剤部門の運営について.令和2年度大学病院情報マネジメント部門連絡会議 (2021年1月、WEB開催) [薬剤セッション]
2. 飯原大稔.ストーリーで理解する臨床研究〜薬局・病院薬剤師が行う研究の基本〜 ストーリーA研究デザイン〜何をどう比較すれば良いか?〜.日本臨床腫瘍薬学会臨床研究セミナー2020 (2021年2月、WEB開催)
3. 飯原大稔、山本扇里、廣瀬智恵美、鈴木昭夫.カルボプラチン誘発悪心・嘔吐に対するオランザピン含有制吐療法の確立に向けて.日本臨床腫瘍薬学会学術大会2021 (2021年3月、WEB開催)
4. 飯原大稔.キャリアパスの転換点:臨床試験のスペシャリストへ.日本臨床腫瘍薬学会学術大会2021 (2021年3月、WEB開催)
5. 廣瀬智恵美、飯原大稔、林秀樹、鈴木昭夫.上皮成長因子受容体チロシンキナーゼ阻害薬の副作用予測のための薬理遺伝学的マーカーの探索.日本臨床腫瘍薬学会学術大会2021 (2021年3月、WEB開催)

学会報告(国内)
1. 早崎容、飯原大稔、下川元継、藤田行代志、安部正和、竹中基記、山本扇里、新井隆広、櫻井美満、森美奈子、中村和人、角暢浩、村瀬紗姫、島岡竜一、坊本佳優、鈴木昭夫、森重健一郎.カルボプラチン療法の悪心・嘔吐予防に対するオランザピンの効果を検証する多施設共同第II相試験.第62回日本婦人科腫瘍学会学術講演会 (2021年1月、WEB開催)